Abstract
Purpose :
To examine the relationship between optical coherence tomography (OCT) images and clinical course in eyes with branch retinal vein occlusion (BRVO) treated with intravitreal ranibizmab (IVR).
Methods :
Of the 30 patients, 27 patients completed this study were performed statistics analyses. Correlations between best-corrected visual acuity (BCVA) or number of IVRs after 12 months and OCT parameters such as external limiting membrane (ELM), ellipsoid zone (EZ), interdigitation zone (IZ), photoreceptor outer segment (PROS) length at first resolution of macular edema (ME) were assessed. The OCT parameters influencing BCVA and number of IVRs were evaluated using multivariate analysis. Correlation between nonperfusion area (NPA) and thinning area, the changes in retinal thickness of BRVO affected area were assessed.
Results :
PROS length at the points of first resolution of ME was significantly correlated with BCVA and number of IVRs at 12 month (p=0.006, r=-0.544, p=0.0008, =-0.661, respectively). In multivariate analysis of variance, PROS length at the points of first resolution of ME had the most significant affected on BCVA and number of IVRs at 12 months (p=0.013, p=0.012, respectively). The size of NPA (9.02±5.34mm) and thinning area (7.22±5.72mm) at macular area (6mm×6mm) showed a significant correlation (p=0.003,r=0.971). The retinal thickness of ischemic BRVO affected area after 10 months were significantly thinner compared with thickness of control area (10 month p=0.001, 11 month p=0.005, 12 month p=0.003). The retinal thickness of nonischemic BRVO affected area at each time points were significantly thicker compared with control area (2 month p=0.007, 3 month p=0.007, 4 month p=0.043, 6 month p=0.046, 7 month p=0.035, 8 month p=0.042, 12 month p=0.028).
Conclusions :
PROS length at points of first resolution of ME was found to be a good indicator of BCVA and number of IVRs in patients with BRVO. The thinning retina in BRVO affected area revealed the retinal ischemia, and is useful to determine a timing of fluorescein angiography.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.